Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Rheumatol. 2020 Nov 1;48(4):504–512. doi: 10.3899/jrheum.200673

Figure 2.

Figure 2.

Probability of a Clinically Meaningful Negative Change in Selected Measures at Second Visit, by Baseline FGF-21 Z-Score. *= p value <0.05. Models include adjustments for age, gender, visceral fat area, current smoking, and methotrexate use (all at baseline). Clinically meaningful worsening was defined as follows, or as patient death before visit (N for each regression is listed as well):
  • HAQ: increased by 0.2 (N=89)
  • SPPB: decreased by 1 (N=51)
  • Extension and flexion strength: decreased by 10% (N=78, 78)
  • Grip strength: decreased by 6.5 kg (N=86)
  • Muscle density and muscle area z-score: decreased by 0.5 (N=82, 76)